Calgary, AB – February 22, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it is undertaking a private placement offering of up to 80,000,000 common shares at a price of $0.01 per share (the “Offering”) for proceeds of up to $800,000. The proceeds [...]

Calgary, AB – February 7, 2023 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, is pleased to announce the closing of its previously announced (see news release of December 20, 2023) non-brokered private placement (the “Placement”) of common shares, and has issued 41,719,250 common shares at [...]

Calgary, AB – February 2, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Further to the Company’s prior news release (January 19, 2024), the Company is providing this bi-weekly default status report (the “Default Status Report”) in [...]

Calgary, AB – TheNewswire - January 19, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following bi-weekly default status report update: Further to the Company’s prior news release (January 5, 2024), the Company is providing this bi-weekly default status report (the “Default Status Report”) in accordance with National Policy 12‑203 Management Cease Trade Orders (“NP 12-203”). On November 20, 2023, UI announced that it would delay the filing of its annual audited financial statements for the [...]

Calgary, AB – TheNewswire - December 20, 2023 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following updates: Appointment of new auditors UI advises that MNP LLP (“MNP”) have been appointed as auditors of the Company, effective December 6, 2023, commencing with the fiscal year ended [...]

Calgary, AB – TheNewswire - December 11, 2023 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that its application for a temporary management case trade order (“MCTO”) has been granted by the Alberta Securities Commission (the “ASC”, as Principal Regulator). UI previously advised (see prior news releases [...]

Calgary, AB - TheNewswire - December 1, 2023 - Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises of the following update and revision to its prior news release which was issued on November 20, 2023. At that time, UI had advised that it has made an application to the [...]

Calgary, AB – November 20, 2023 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it has made an application to the Alberta Securities Commission (as Principal Regulator) and the British Columbia Securities Commission, to approve a temporary management case trade order (“MCTO”) under National [...]

Calgary, AB - TheNewswire - October 12, 2023 - Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises of the following changes to its Board of Directors, effective October 11, 2023: UI has appointed two new members to serve on the Company’s Board of Directors (the “Board”) to replace two [...]